CDK4-话题@MedSci

#CDK4#

49篇内容 | 939人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1703077, encodeId=37021e0307772, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=Nature：惊人发现！“重磅抗癌药”CDK4/6抑制剂竟然也是免疫疗法, objectType=article, longId=110335, objectId=e6bf1103359b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6bf1103359b, replyNumber=0, likeNumber=44, createdTime=2018-05-29, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6bf1103359b, moduleTitle=Nature：惊人发现！“重磅抗癌药”CDK4/6抑制剂竟然也是免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6bf1103359b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703076, encodeId=8a821e0307690, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=Oncologist:乳腺癌CDK4/6抑制剂治疗的潜在副作用都有啥？, objectType=article, longId=106365, objectId=2cb21063650c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb21063650c, replyNumber=0, likeNumber=36, createdTime=2018-05-24, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb21063650c, moduleTitle=Oncologist:乳腺癌CDK4/6抑制剂治疗的潜在副作用都有啥？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb21063650c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703078, encodeId=c65d1e03078b0, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=[SIBCS2017]在故事开始的地方，Richard S. Finn教授谈CDK4/6抑制剂成功的漫漫长路, objectType=article, longId=117554, objectId=372411e55468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=372411e55468, replyNumber=0, likeNumber=35, createdTime=2018-03-26, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=372411e55468, moduleTitle=[SIBCS2017]在故事开始的地方，Richard S. Finn教授谈CDK4/6抑制剂成功的漫漫长路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=372411e55468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703080, encodeId=b0971e0308036, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=CLIN CANCER RES：肢端黑色素瘤CDK4通路基因改变表明CDK4/6抑制可以作为靶向疗法, objectType=article, longId=121178, objectId=6c591211e82d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c591211e82d, replyNumber=0, likeNumber=29, createdTime=2018-07-28, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c591211e82d, moduleTitle=CLIN CANCER RES：肢端黑色素瘤CDK4通路基因改变表明CDK4/6抑制可以作为靶向疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c591211e82d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703079, encodeId=9cf01e03079d4, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=Nature：CDK4/6抑制剂--ER+乳腺癌治疗新选择!, objectType=article, longId=118337, objectId=fa9711833ec4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9711833ec4, replyNumber=0, likeNumber=25, createdTime=2018-10-10, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9711833ec4, moduleTitle=Nature：CDK4/6抑制剂--ER+乳腺癌治疗新选择!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa9711833ec4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703075, encodeId=736b1e0307525, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=Nature：这一指标可预测CDK4/6抑制剂抗癌效果, objectType=article, longId=101718, objectId=b103101e18e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b103101e18e7, replyNumber=0, likeNumber=34, createdTime=2018-03-04, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b103101e18e7, moduleTitle=Nature：这一指标可预测CDK4/6抑制剂抗癌效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b103101e18e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703074, encodeId=75361e030741a, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）, objectType=article, longId=70373, objectId=0c80e0373e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c80e0373e2, replyNumber=0, likeNumber=30, createdTime=2016-11-29, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c80e0373e2, moduleTitle=ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c80e0373e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703072, encodeId=55851e030720e, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=辉瑞CDK4/6抑制剂palbociclib II期达主要终点, objectType=article, longId=33003, objectId=65bc330037a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65bc330037a, replyNumber=0, likeNumber=29, createdTime=2014-11-18, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65bc330037a, moduleTitle=辉瑞CDK4/6抑制剂palbociclib II期达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65bc330037a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703073, encodeId=8fa91e0307307, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=以CDK4/6为靶点的三种乳腺癌新药均取得不俗进展能延长晚期乳癌患者生命, objectType=article, longId=33202, objectId=9d173320207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d173320207, replyNumber=0, likeNumber=41, createdTime=2014-05-04, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d173320207, moduleTitle=以CDK4/6为靶点的三种乳腺癌新药均取得不俗进展能延长晚期乳癌患者生命, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d173320207)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CDK4

2020-05-29

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

Nature：惊人发现！“重磅抗癌药”CDK4/6抑制剂竟然也是免疫疗法

2018-05-29

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

Oncologist:乳腺癌CDK4/6抑制剂治疗的潜在副作用都有啥？

2018-05-24

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

[SIBCS2017]在故事开始的地方，Richard S. Finn教授谈CDK4/6抑制剂成功的漫漫长路

2018-03-26

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

CLIN CANCER RES：肢端黑色素瘤CDK4通路基因改变表明CDK4/6抑制可以作为靶向疗法

2018-07-28

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

Nature：CDK4/6抑制剂--ER+乳腺癌治疗新选择!

2018-10-10

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

Nature：这一指标可预测CDK4/6抑制剂抗癌效果

2018-03-04

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）

2016-11-29

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

辉瑞CDK4/6抑制剂palbociclib II期达主要终点

2014-11-18

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

以CDK4/6为靶点的三种乳腺癌新药均取得不俗进展能延长晚期乳癌患者生命

2014-05-04

科室
- - 订阅+
  - 更多科室
工具
服务